Aberrant activation of the MET/hepatocyte growth factor (HGF) receptor participates in the malignant behavior of cancer cells, such as invasion-metastasis and resistance to molecular targeted drugs. Many mutations in the MET extracellular region have been reported, but their significance is largely unknown. Here, we report the dysregulation of mutant MET originally found in a lung cancer patient with Val370 to Asp370 (V370D) replacement located in the extracellular SEMA domain. METknockout cells were prepared and reconstituted with WT-MET or V370D-MET. HGF stimulation induced MET dimerization and biological responses in cells reconstituted with WT-MET, but HGF did not induce MET dimerization and failed to induce biological responses in V370D-MET cells. The V370D mutation abrogated HGF-dependent drug resistance of lung cancer cells to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). Compared with WT-MET cells, V370D-MET cells showed different activation patterns in receptor tyrosine kinases upon exposure to survival/ growth-stressed conditions. Surface plasmon resonance analysis indicated that affinity between the extracellular region of V370D-MET and HGF was reduced compared with that for WT-MET. Further analysis of the association between V370D-MET and the separate domains of HGF indicated that the SP domain of HGF was unchanged, but its association with the NK4 domain of HGF was mostly lost in V370D-MET.
| INTRODUC TI ON
Activation of MET receptor tyrosine kinase (RTK) plays a well-defined role as a driver of oncogenesis and progression to malignant tumors. 1, 2 The MET receptor is biosynthesized as a single-chain precursor of ~190 kDa, which undergoes cleavage by furin during transport to the cell membrane. 3 The resulting mature form is composed of a covalently linked 50-kDa α-chain and a membrane-spanning 145-kDa β-chain. 4 The extracellular domain (ECD) of the MET receptor consists of SEMA, PSI, and IPT1-4 domains, and the intracellular region contains juxtamembrane and tyrosine kinase (TK) domains. 5 The ligand for MET is hepatocyte growth factor (HGF), which is composed of NK4 (N-terminal and four kringle domains, also known as the α-chain) and SP (also known as the β-chain) domains linked by a disulfide bridge. 6 Activation of the HGF/MET pathway results in pleiotropic biological activities including on cell proliferation, migration, survival, and morphogenesis. 6, 7 Aberrant activation of MET by ligand-dependent or ligand-independent mechanisms is associated with cancer development, metastasis, and drug resistance. 2, 6, 8 Germline and somatic mutations of MET receptor were found in many malignancies. 9, 10 Mutations in the MET tyrosine kinase domain (H1094Y/R, H1106D, M1131T, V1188L, L1195V, D1228H/N, Y1230C/D/H, M1250T/I) affect kinase activation and are likely to be gain-of-function mutations. 6, 10, 11 Deletion of the juxtamembrane domain of MET caused by exon 14 skipping resulted in decreased MET degradation and prolonged downstream signaling activation. 12 Two missense mutations in the MET juxtamembrane domain in small-cell lung cancer patients increased tyrosine phosphorylation of cellular proteins. 13 Thus, signal abnormalities and the significance of mutations in the intracellular domains of MET have been defined. In contrast, approximately 20 different mutations in the MET extracellular domains were found in cancer patients; however, except for a few cases, their significance and underlying mechanisms remain unknown. 6, 11, 14 N375S is a missense mutation in the MET SEMA domain found in 13% of East Asian lung tumor patients. Studies based on HGF binding, molecular modeling, and apoptosis induced by MET inhibitors indicated that the N375S mutation conferred mild resistance to MET inhibition. 15 Recently, the N375K mutation was identified in four siblings affected by epidermal growth factor receptor (EGFR)-mutant lung adenocarcinomas. 16 Thus, N375 is a "hotspot" for mutations and may play an important role in the normal functions of MET receptor. Here, we focus on the V370D missense mutation originally found in lung adenocarcinoma, 11, 14 because V370 is located in the same α-helix-367-375 structure as the hotspot N375. We obtained evidence that V370D-MET is a loss-of-function mutation.
| MATERIAL S AND ME THODS

| Cells, reagents, and recombinant proteins
CHO-K1 cell line was obtained from ATCC and cultured in Ham's F12 medium (FUJIFILM Wako Pure Chemical, Osaka, Japan) supplemented with 5% FBS (Sigma-Aldrich, St Louis, MO, USA).
Human lung adenocarcinoma PC-9 cells, kindly provided by Prof. Seiji Yano (Kanazawa University, Japan), were cultured in RPMI-1640 medium (FUJIFILM Wako Pure Chemical) supplemented with 10% FBS. HGF was prepared from the conditioned medium of CHO cells stably expressing human HGF. NK4 was kindly provided by Kringle Pharma (Ibaraki, Osaka, Japan). PHA665752 was purchased from Selleck Biotech (Tokyo, Japan). Anti-pMET (Y1234/1235), anti-MET, anti-pAKT (S473), and anti-GAPDH antibodies were purchased from Cell Signaling Technology Japan (Tokyo, Japan). For the expression of MET extracellular domains (MET-ECD-Fc-His or MET-ECD-His), expression constructs were transiently transfected into Expi293F cells using the ExpiFectamine 293 Transfection Kit (ThermoFisher Scientific, Waltham, MA, USA). Secreted proteins were purified using cOmplete His-Tag Purification Resin (Sigma-Aldrich). 
| MET-knockout cells
| Plasmids
Human MET cDNA (NP_000236.2) was inserted into the pCAGGS plasmid, 17 and a flag-tag sequence (GACTACAAGGACGATGACGACAAG) was connected to the 3′ end of it. For pCAGGS-hMET-ECD-His, cDNA fragments were amplified by PCR from pCAGGS-hMET-Flag using the following primer sets: HindIII-hMET-Fo and PacI-hMET-ECD-Re.
After ligation with the synthesized DNA fragment PacI-GGGS-7His-STOP-NotI, the HindIII-hMET-ECD-GGGS-His-STOP-NotI DNA fragment was cloned into HindIII-NotI sites of pCAGGS-hMET-Flag.
For pCAGGS-hMET-ECD-Fc-His, a cDNA library was prepared from pEF-Fc 18 transfected EHMES-1 cells. Human IgG fragment crystallizable region (Fc) cDNA was amplified by PCR using the following primers from the cDNA library: PacI-Fc-Fo and KpnI-Fc-Re. After ligation with the synthesized DNA fragment KpnI-GGGS-7His-Stop-NotI, PacI-Fc-GGGS-His-NotI DNA was cloned into PacI-NotI sites of pCAGGS-hMET-ECD-His. For mutation-containing pCAGGS-hMET-ECD-His plasmids, mutagenesis PCR was carried out using WT pCAGGS-hMET-ECD-His as a template for V370D primers. Detailed information on the primers and synthesized DNA sequences is presented in Table 1 . For mutation-containing pCAGGS-hMET-ECD-Fc-His and pCAGGS-hMET-Flag plasmids, cDNA fragments containing mutation sites were purified on agarose gel after digesting mutationcontaining pCAGGS-hMET-ECD-His by HindIII and MfeI, and were cloned into HindIII-MfeI sites of pCAGGS-hMET-ECD-Fc-His and pCAGGS-hMET-Flag, respectively.
| Stable transfection
pCAGGS-hMET-Flag (WT or V370D mutant) and hygromycin-resistant plasmid were cotransfected in a 10:1 ratio into CHO-METKO or
PC-9 METKO cells in 60-mm dishes using Lipofectamine LTX with
Plus transfection reagent (ThermoFisher Scientific) according to the manufacturer's instructions. After 24 hours, cells were selected by culturing in growth medium supplemented with Hygromycin B (for CHO METKO cells, 300 μg/mL; for PC-9 METKO cells, 100 μg/mL) for 10 days. Stably expressing cells were obtained through limiting dilution and confirmed by western blotting using anti-MET antibody. Corning, Corning, NY, USA). Cells (2 × 10 4 ) were seeded into the upper insert and cultured for 24 hours. They were fixed with 4% paraformaldehyde in PBS and cells attached to the lower side of the insert were stained with 0.2% crystal violet in 20% methanol.
| Western blot and RTK array analysis
| Biological assays
| Receptor dimerization
Receptor dimerization on living cells in culture was done by chemical crosslinking, as described elsewhere. 19 Briefly, cells (2 × 10 6 ) were seeded in 60-mm dishes and cultured overnight. After washing twice with ice-cold Ham's F12 medium supplemented with 5% FBS, cells were stimulated with HGF in Ham's F12 supplemented with 5% FBS
TA B L E 1 Primers and DNA sequences used for plasmid construction
Name
Sequence
for 60 minutes at 4°C. They were then washed with ice-cold PBS three times and treated with 1 mmol/L bis(sulfosuccinimidyl)suberate (BS3; ThermoFisher Scientific) in PBS for 60 minutes at 4°C.
Unreactive BS3 was quenched with 50 mmol/L Tris (pH 8.0) and 150 mmol/L NaCl for 15 minutes at 4°C. MET receptors enriched by immunoprecipitation from cell lysate were subjected to SDS-PAGE and western blot using anti-MET antibody (25H2; Cell Signaling Technology Japan), followed by HRP-conjugated antimouse IgG (Dako), and then visualized by chemiluminescent reaction using
ImmunoStar LD (FUJIFILM Wako Pure Chemical).
| Flow cytometry
Cells were stained with FITC-conjugated anti-MET antibody (eBioclone 97; ThermoFisher Scientific) in PBS supplemented with 2% FBS for 30 minutes at 4°C. After washing, analysis was carried out using FACSCanto II (Becton Dickinson, Franklin Lakes, NJ, USA). The beads were washed three times with lysis buffer and treated with SDS-PAGE Laemmli sample buffer supplemented with 5% mercaptoethanol. Samples were then subjected to western blot. Eluted fractions were subjected to SDS-PAGE using a 5%-20% polyacrylamide gradient gel and stained using a Rapid CBB Stain Kit (Nacalai Tesque, Kyoto, Japan). 
| Cell surface biotinylation
| Size-exclusion chromatography analysis
| Surface plasmon resonance analysis
| Statistical analysis
Data were analyzed by one-way ANOVA followed by Tukey's multiple comparison tests using GraphPad Prism 7. P-values <.05 were considered statistically significant.
| RE SULTS
| MET-V370D is inefficiently cleaved and largely loses its response to HGF
Outlines of the structures of MET and HGF, and the position of the V370D mutation are shown in Figure 1A . Val370 is located in the α-helix (amino acids 367-375, shown in red in Figure 1B 
| V370D abrogates HGF-dependent EGFR-TKI resistance in PC-9 tumor cells
Involvement of the HGF-MET receptor pathway in resistance against EGFR-TKI was well characterized in previous studies. [20] [21] [22] To test whether the V370D mutation affects EGFR-TKI resistance, we prepared PC-9 human lung adenocarcinoma cells deficient in endogenous MET receptor (PC-9 METKO) ( Figure 3A) . These cells were manipulated to stably express human wild-type MET (PC-9 WT) or V370D mutant MET (PC-9 V370D) at similar levels ( Figure 3B ). In PC-9 METKO cells, MET was undetectable and HGF failed to induce p-MET and p-AKT, whereas HGF increased p-MET and p-AKT levels in PC-9 WT cells ( Figure 3A,B) . In contrast, basal phosphorylation levels of p-MET and p-AKT were different related to clonal variation (#1 and #2); however, p-MET and p-AKT levels were unchanged or marginally increased by HGF in PC-9 V370D cells ( Figure 3B ).
We next examined the resistance characteristics of PC-9 lung cancer cells to EGFR-TKI gefitinib. In PC-9 WT cells, cell growth was inhibited by gefitinib, but HGF rescued cell growth dose-dependently even in the presence of gefitinib ( Figure 3C ). PC-9 V370D growth was inhibited by gefitinib; however, HGF did not rescue cell growth inhibited by gefitinib. Taken together, these results indicate that HGF hardly activates V370D-MET, which is associated with impaired biological responses to HGF.
Because N375S mutant MET conferred mild resistance to MET-TKI, 15 we tested the sensitivity of V370D-MET to MET-TKI ( Figure 3D ). Sensitivity to PHA665752 MET-TKI was not changed between wild-type MET and V370D mutant MET. To further address the potential involvement of V370D mutant MET in regulating cell characteristics, CHO cells expressing wild-type or V370D-MET were cultured under survival/growth-stressed conditions induced by low-level FBS in the presence of HGF and the change in phosphorylation of RTK was analyzed ( Figure 3E ). RTK array analysis indicated that the phosphorylation level of platelet-derived growth factor receptor-β (PDGFRβ) was higher in CHO-V370D cells than in CHO-WT cells. This implies that V370D-MET may influence the availability or activation status of RTK under certain conditions. Figure 4B ).
| MET-V370D is normally located on the cell surface but is not dimerized by HGF
Using another approach, the localization of MET was tested by the biotinylation of cell surface proteins labeled with NHS-biotin, solubilized, pulled down using streptavidin beads, and subjected to western blotting with anti-MET antibody. The levels of biotinylated MET were comparable between CHO-WT and CHO-V370D cells ( Figure 4C ). Thus, MET-V370D is translocated to the cell membrane comparably to MET-WT.
| V370D mutation decreases MET-HGF binding ability by blocking NK4 binding
To further investigate the mechanism underlying how the V370D mutation affects HGF-induced MET receptor dimerization, the binding properties of MET-WT and MET-V370D to HGF were analyzed.
Extracellular domains of MET-WT (MET-ECD-WT) and MET-V370D
(MET-ECD-V370D) were prepared and their associations were analyzed by size-exclusion chromatography and SDS-PAGE ( Figure 5 ).
The elution profile of a mixture of HGF and MET-ECD-WT indicated that MET-ECD-WT was eluted with HGF as a major peak and the position of the major peak was shifted to earlier fractions than those of individual MET-ECD-WT and HGF (Figure 5, left) . Protein staining after SDS-PAGE indicated that the major peak was composed of MET-ECD-WT and HGF. This indicates that MET-ECD-WT associates with HGF. In contrast, for mixtures of MET-ECD-V370D and HGF, the elution profile indicated that these proteins formed two peaks, the positions of which were similar to those of individual MET-ECD-V370D and HGF (Figure 5, right) . Protein staining of these peaks indicated a marginal band for HGF that was present in earlier and major fractions for MET-ECD-V370D, but MET-ECD-V370D and HGF were eluted separately. Therefore, MET-ECD-V370D has a low association with HGF in solution.
To further evaluate the association between MET-ECD and HGF, association kinetics was analyzed by SPR ( Figure 6A ). MET-ECD- showed low binding affinity to MET-ECD-Fc-V370D and the K D value could not be calculated ( Figure 6C ). Taken together, these results demonstrate that the V370D mutation in MET impairs association with the NK4 domain in HGF, which decreases its association with HGF. interactions of the α-helix with NK4/HGF or structural changes that affect α-helix orientation. In this context, a missense mutation of Asn375 located in α-helix-367-375 is consistently found in different types of malignant tumors including lung cancer. 11, 14 Asn375 to Lys375 replacement in MET reduced the affinity to HGF. 16 Taking these findings together, α-helix-367-375 may play a role in the association with HGF; thus, a change in orientation and/ or position of α-helix-367-375 might affect interactions between MET and HGF.
| D ISCUSS I ON
The N375K missense mutation in MET was identified by wholeexome sequencing as the most likely causative mutation found in siblings affected by lung adenocarcinoma with EGFR mutation. 16 Functional analysis of Asn375 to Lys375 replacement indicated that the association of HGF with Lys375-MET was reduced and biological responses to HGF in cells expressing this mutant MET were decreased compared with those for wild-type Asn375-MET, 16 indicating that N375K is a partial loss-of-function mutation of the MET receptor. MET with mutation located in the TK domain is constitutively active or susceptible to activation, and such gain-of-function mutations in RTK play a constitutive role in oncogenic alterations of cells. How loss-of-function mutations are associated with progression to malignant diseases cannot be explained. However, a recent study indicated that an inactive Braf mutation augmented MAPK signaling through the compensatory regulation of intracellular signaling, which promoted lung adenocarcinoma. 26 An inactivating F I G U R E 6 Binding of hepatocyte growth factor (HGF), SP, and NK4 to MET-WT and MET-V370D. Binding kinetics of HGF (A), SP (B), and NK4 (C) to MET-WT or MET-V370D was measured by surface plasmon resonance (SPR) analysis. In (A), biotinylated HGF was immobilized on a sensor chip and binding of MET-ECD-Fc (WT or V370D) was measured (n = 2). In (B) and (C), MET-ECD-Fc-His (WT or V370D) was immobilized on a sensor chip and binding of SP or NK4 was measured (n = 2) mutation in a signaling molecule may provide intrinsic pressure to replace signal activation. We found a difference in activation status in RTK between the cells expressing wild-type and V370D-MET under survival/growth-stressed conditions. Although we cannot rule out the possibility that V370D mutations in lung adenocarcinoma patients 14 are passenger mutations that do not substantially participate in the oncogenic process, the V370D mutation may change the dependence on other RTK and/or downstream signaling molecules, which may allow the expansion of cancer cells with V370D mutant MET under certain conditions.
